Answers are grounded in this paper and cite their sources.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide modestly reduces ALT in HIV-positive individuals, suggesting a favorable option for those with HBV.
Switching from TDF to TAF is associated with modest but statistically significant ALT reduction in PWH, especially in HBsAg + individuals. Our findings suggest that TAF may represent a favourable option in this subgroup, although potential metabolic consequences warrant close monitoring.
No takes yet. Share an insight, caveat, or question.
Lapadula et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: